Loading clinical trials...
Loading clinical trials...
Single Dose, Double-blind, Double-dummy, 3 Period Cross-over, Placebo Controlled Clinical Trial to Assess the Reate of Onset of Action of Inhaled Aclidinium Bromide 200µg Compared to Placebo and Tiotropium 18µg in Patients With Chronic Obstructive Pulmonary Disease (COPD).
This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.
This is a single dose, randomised, double-blind, double-dummy, 3 period cross-over, placebo controlled, multinational, multicentre trial.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Respiratory Clinical Trials Ltd
London, United Kingdom
Start Date
February 1, 2007
Primary Completion Date
August 1, 2007
Completion Date
August 1, 2007
Last Updated
November 17, 2016
115
ACTUAL participants
Aclidinium bromide
DRUG
Placebo Tiotropium
DRUG
Tiotropium
DRUG
Placebo LAS34273
DRUG
Lead Sponsor
AstraZeneca
NCT07477600
NCT07382258
NCT07195838
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions